Life Sciences, RNA Editing
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE stock's potential in this $10B market.
Wave Life Sciences Stock Climbs on RNA Editing Progress
Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease. T
Wave Life Sciences: Buy Rating Affirmed on Promising RNA Editing Platform Data
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.
RNA-editing stocks soar on Wave Life’s breakthrough trial data
Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment. Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases.
Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
Merck KGaA Trims Health Care And Life Sciences Targets, Eyes M&A
Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...
bovnews8h
180 Life Sciences Corp (ATNF) Stock Trading Recap
In recent trading, 180 Life Sciences Corp (ATNF) stock price has shown some volatility, fluctuating 372.26% over the last five trades and 225.13% over the past 30 trades. This represents a notable ...
Lupus Foundation of America2h
UPDATE: Kezar Life Sciences Terminates Phase 2b Study of Zetomipzomib for Lupus Nephritis Treatment
Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...
Agilent Technologies in Chicopee scores life sciences tax incentive, commits to adding 10 jobs
CHICOPEE — Agilent Technologies in Chicopee received a $250,000 life sciences tax incentive and has committed to adding 10 ...
JD Supra1d
Healthcare & Life Sciences Private Equity Deal Tracker: GTCR to Acquire TRANZACT
GTCR has announced it will acquire TRANZACT. TRANZACT, founded in 1997 and based in Fort Lee, New Jersey, is a ...
Upstream Bio Leads Life Sciences IPOs With Upsized Listing
Two of three US life-sciences companies have so far exceeded or met their goals in initial public offerings Thursday, showing ...
Inside Harlem’s unlikely ‘life-sciences’ boom
The $700 million Taystee Lab Building sits in the Manhattanville Factory District, but the laboratory goes beyond West Harlem ...
Philadelphia life sciences leasing approaches ‘light at the end of the tunnel’
Stagnant for more than a year, Philadelphia’s life sciences leasing market is starting to percolate and industry insiders are ...
What's Up Newp28m
Rhode Island Life Science Hub funds research, workforce development
The Rhode Island Life Science Hub announced today that it has awarded $128,810 in grants to fourteen different organizations in the state. This second round of funding aims to bolster Rhode Island’s ...
5 things to know about the Texas Research Quarter, the life sciences hub planned for Plano
The Texas Research Quarter is betting big on making Plano and North Texas a hub for life sciences. The development by ...
The Canadian Press on MSN2d
In ‘hard pivot,’ Ontario to invest $146 million as part of life sciences strategy
TORONTO - Ontario is making what a key minister describes as a "hard pivot" to life sciences, as it looks to replicate its ...